Goodwin Advised AI Proteins on $41.5 Million Series A Financing
Goodwin Advised AI Proteins on $41.5 Million Series A Financing
The Goodwin team advised AI Proteins on its $41.5 million Series A financing, which will support the company’s development of a new class of de novo miniprotein therapeutics. The round was led by Mission BioCapital and Santé Ventures, with participation from existing investors, including Lightchain Capital and Cobro Ventures. AI Proteins is leveraging its AI-enabled discovery platform to create purpose-built, modular miniproteins designed entirely from first principles, enabling precise control over function and pharmacology across a broad range of therapeutic applications.
The company has also adopted a hub-and-spoke business model to protect and expand its core platform and drive long-term innovation. This new model will allow the company to spin out individual programs and focus investors and partners on maximizing discovery and value from each new asset.
Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-enabled design and a high-throughput drug discovery platform, AI Proteins creates de novo miniproteins optimized for a variety of therapeutic applications. Partnered with leading biopharmaceutical companies, AI Proteins continues to pursue collaborations across a wide variety of therapeutic areas in addition to advancing its internal pipeline. The AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies.
The Goodwin team was led by Mitchell Bloom (Partner), Shoaib Ghias (Partner), and Bartek Sudol (Associate), Minji Kim (Associate), Angela Kim (Associate), Ogechika Oselukwue (Associate), and Duncan Greenhalgh (Partner), and Maria Smith (Associate), Suzanne Nguyen (Associate).
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.
